Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study
Ramón García‐Sánz, Roger G. Owen, Wojciech Jurczak, Meletios A Dimopoulos, Helen O. McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cohen, Constantine S. Tam (2025). Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. , 9(24), DOI: https://doi.org/10.1182/bloodadvances.2024015596.
